The United States Food and Drug Administration (FDA) has granted Cynata Therapeutics Orphan Drug Designation for CYP-001 for the treatment of acute graft versus host disease (GvHD).    CYP-001 is the lead mesenchymal stem cell (MSC) product manufactured using Cynata’s proprietary Cymerus platform manufacturing technology.   GvHD is a complication that can occur after a bone marrow transplant or similar procedure, when the donor’s immune cells (from the “graft”) attack the recipie...